

DPC BIOSCIENCES CORPORATION ANNOUNCES APPOINTMENT OF CHRISTOPHER S. KAPE, PRESIDENT AND CEO, TO ITS BOARD OF DIRECTORS:

MONTREAL, CANADA, Tuesday, December 20th, 2005– (TSX Venture Exchange: DPC.H)

Morden C. Lazarus, Chairman of DPC Biosciences Corporation (the “Company”) announces today that Christopher S. Kape, President and CEO, has been named to the Board of Directors, effective December 20th, 2005. Christopher S. Kape became President and CEO of the Company on Tuesday, December 13th, 2005.

The Chairman is also pleased to announce today that the Company proposes to effect a non brokered private placement to raise up to \$450,000.00 at \$0.05 per share to close on or before January 30th, 2006.

Christopher S. Kape, President and CEO, also wishes to announce the resignation of Albert Barbusci a Director of the Company and Anthony Barbusci, CFO, effective December 20th, 2005.

Mr. Kape said, "I would like to express my appreciation and personal gratitude for Albert and Anthony Barbuscis' contribution to the Company in maintaining its status as a publicly traded vehicle in difficult times."

For additional information:

Contact: Christopher S. Kape

PH: (604) 639-5835

E: chris@dpcbio.com

THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR THE ACCURACY OF THE INFORMATION CONTANIED IN THE NEWS RELEASE.